title: Phase I study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromes.
abstract: Overexpression of P-glycoprotein (P-gp) in cancer cells reduces intracellular accumulation of various anticancer drugs including anthracyclines and vinca alkaloids. This multidrug resistance (MDR) phenotype can be reversed in vitro by a number of non-cytotoxic drugs. We have identified the quinine's isomer cinchonine as a potent MDR reversing agent, both in vitro and in animal models. Here, we report an open phase I dose escalation trial in patients with refractory or relapsed malignant lymphoid diseases. Cinchonine dihydrochloride was administered by continuous i.v. infusion for 48 h and escalated over five dose levels ranging from 15 to 35 mg/kg/d. Cinchonine infusion started 24 h before i.v. doxorubicin (25 mg/m2), vinblastine (6 mg/m2), cyclophosphamide (600 mg/m2) and methylprednisolone (1 mg/kg/d) (CHVP regimen) and lasted for 24 h after chemotherapy infusion. Thirty-four patients received 87 cycles of CHVP/cinchonine. The MTD of cinchonine administered by continuous i.v. infusion was 30 mg/kg/d. Prolonged cardiac repolarization was the main dose-limiting toxicity. No ventricular arrhythmia including 'torsade de pointes' was observed. An MDR reversing activity was identified in the serum from every patient and correlated with cinchonine serum level. When infused at 30 mg/kg/d, cinchonine demonstrated a limited influence on doxorubicin pharmacokinetic. We conclude that i.v. infusion of cinchonine might be started 12 h before MDR-related chemotherapy infusion and requires continuous cardiac monitoring but no reduction of cytotoxic drug doses.
authors.affiliation: Clinical Hematology Unit, CHU Le Bocage, Dijon, France.
authors.forename: E
authors.initials: E
authors.lastname: Solary
authors.forename: L
authors.initials: L
authors.lastname: Mannone
authors.forename: D
authors.initials: D
authors.lastname: Moreau
authors.forename: D
authors.initials: D
authors.lastname: Caillot
authors.forename: R O
authors.initials: RO
authors.lastname: Casasnovas
authors.forename: H
authors.initials: H
authors.lastname: Guy
authors.forename: M
authors.initials: M
authors.lastname: Grandjean
authors.forename: J E
authors.initials: JE
authors.lastname: Wolf
authors.forename: F
authors.initials: F
authors.lastname: André
authors.forename: P
authors.initials: P
authors.lastname: Fenaux
authors.forename: P
authors.initials: P
authors.lastname: Canal
authors.forename: B
authors.initials: B
authors.lastname: Chauffert
authors.forename: A
authors.initials: A
authors.lastname: Wotawa
authors.forename: M
authors.initials: M
authors.lastname: Bayssas
authors.forename: P
authors.initials: P
authors.lastname: Genne
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002930:Cinchona Alkaloids / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D018432:Drug Resistance, Multiple; D019008:Drug Resistance, Neoplasm; D004562:Electrocardiography; D005260:Female; D006321:Heart / Q000187:drug effects; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008232:Lymphoproliferative Disorders / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D012008:Recurrence; D013713:Teniposide / Q000008:administration & dosage
chemical_list: D002930:Cinchona Alkaloids; D004317:Doxorubicin; D003520:Cyclophosphamide; D013713:Teniposide; C010086:cinchonine; D011241:Prednisone